10-Q quarterly report · filed Nov 4, 2026

Solid Biosciences Inc. (SLDB) Q3 2026 10-Q Quarterly Report

Short answer

Solid Biosciences Inc. (SLDB) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$54M
−17.9% YoY · +1.6% QoQ
EPS (diluted)
−$0.35
+27.1% YoY · +2.8% QoQ

Source: XBRL data from the Solid Biosciences Inc. (SLDB) Q3 2026 10-Q on SEC EDGAR. USD.

Solid Biosciences Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, no commercial product revenue, unchanged from prior-year quarter
  • Net loss $53.9M vs $45.8M YoY, operating expenses $57.7M vs $48.1M
  • Best-performing program SGT-212, R&D expense $4.4M, up 144.3% YoY
  • Cash, equivalents and securities $348.9M, sufficient into first half of 2028
  • Operating cash use $145.4M, financing provided $303.4M, including $226.3M private placement proceeds

Risk Factors

  • Newly added regulatory risk: evolving FDA trial-design expectations may require randomized trials, larger populations or longer follow-up
  • Most material regulatory update: FDA workforce reductions and proposed HHS budget cuts could delay IND and BLA reviews
  • Operational risk: transient-transfection manufacturing remains complex, with capacity constraints potentially delaying clinical supply
  • Competitive risk: Sarepta’s ELEVIDYS approval and competitors’ Duchenne programs intensify pressure on SGT-003
  • Financial risk: cash, cash equivalents and securities expected to fund operations only into the first half of 2028

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Solid Biosciences Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.